Kreuter, Michael
Bendstrup, Elisabeth
Jouneau, Stéphane
Maher, Toby M.
Inoue, Yoshikazu
Miede, Corinna
Lievens, Dirk
Crestani, Bruno
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
https://doi.org/10.1186/s12931-022-01974-2
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
https://doi.org/10.1136/bmj-2021-066354
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
https://doi.org/10.1136/bmjresp-2017-000212
Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
https://doi.org/10.1136/bmjresp-2021-001167
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
https://doi.org/10.1186/s12931-023-02371-z
P163 A multicentre retrospective cohort comparison of aetiology and survival in patients with chronic hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis
https://doi.org/10.1136/thorax-2018-212555.321
Funding for this research was provided by:
The INBUILD trial was funded by Boehringer Ingelheim.
Article History
Received: 12 January 2023
Accepted: 20 February 2023
First Online: 9 March 2023
Declarations
:
: The INBUILD trial was conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and was approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating center. All patients provided written informed consent before study entry.
: Not applicable.
: Michael Kreuter reports grants, consulting fees and fees for speaking from Boehringer Ingelheim (BI) and Roche; and holds leadership or fiduciary roles with Deutsche gesellschaft für Pneumologiex, the European Respiratory Society, and the German Respiratory Society. Elisabeth Bendstrup reports an unrestricted grant from BI; fees for speaking from BI, Chiesi, Roche; support for travel from BI and Roche; and has participated on Data Safety Monitoring Boards or Advisory Boards for AbbVie and BI. Stéphane Jouneau reports grants from AIRB, BI, LVL, Novartis, Roche; fees for speaking from AIRB, AstraZeneca, BI, Bristol Myers Squibb, Chiesi, Genzyme, GlaxoSmithKline, LVL, Novartis, Pfizer, Roche, Sanofi; support for travel from BI and Roche; and has participated on Data Safety Monitoring Boards or Advisory Boards for BI, Novartis, Roche. Toby M. Maher reports consulting fees from AstraZeneca, Bayer, Blade Therapeutics, BI, Bristol Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant, Respivant, Roche/Genentech, Theravance Biopharma, Veracyte; and fees for speaking from BI and Roche/Genentech. Yoshikazu Inoue reports grants from the Japan Agency for Medical Research and Development and the Japanese Ministry of Health, Labour, and Welfare; fees for lectures from BI, Kyorin, Shionogi, Thermo Fisher; and has served as a consultant or steering committee member for BI, Roche, Savara, Taiho. Corinna Miede is an employee of mainanalytics GmbH, Sulzbach (Taunus), Germany, which was contracted by BI to assist with these analyses. Dirk Lievens is an employee of BI. Bruno Crestani reports grants from BI, Bristol Myers Squibb, Roche; consulting fees from Apellis; fees for speaking from AstraZeneca, BI, Bristol Myers Squibb, Chiesi, Novartis, Roche, Sanofi; and medical writing support from Translate Bio (Sanofi).